Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03429556
Other study ID # EB001-ABD201
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 8, 2018
Est. completion date July 10, 2018

Study information

Verified date August 2019
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the safety and efficacy of single intra-operative treatment of Botulinum Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA) in participants undergoing abdominoplasty.


Recruitment information / eligibility

Status Terminated
Enrollment 23
Est. completion date July 10, 2018
Est. primary completion date July 10, 2018
Accepts healthy volunteers No
Gender All
Age group 23 Years to 55 Years
Eligibility Inclusion Criteria:

1. Men or women 23 to 55 years of age, inclusive

2. Scheduled to undergo elective abdominoplasty surgery with full length plication from xyphoid to pubis, and removal of skin/fat flap under general anesthesia (endotracheal or otherwise) without liposuction

3. American Society of Anesthesiologist (ASA) Physical Class 1-2.

Exclusion Criteria:

1. History of prior major abdominal surgery as judged by the investigator

2. Pre-existing lung disease that could impact participant safety in the opinion of the investigator

3. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton- Lambert syndrome, or amyotrophic lateral Sclerosis)

4. At high risk of deep vein thrombosis as judged by the investigators determined by a Caprini score of 3 or higher

5. Slow vital capacity that is below 80% of normal value for respective race, age, height, and gender or below 2.5 Liters (L) of absolute volume

6. Pulse oximetry below 95%

7. Body weight less than 50 kg (110 pounds) or a Body Mass Index (BMI) of = 32

8. Reported use of any botulinum toxin within 3 months prior to the date of surgery

9. Use of long acting opioids within 3 days or any opioid medication within 24 hours prior to surgery

10. Aminoglycoside intake within 48 hours prior to or during surgery

11. Participants on anti-depressant or anti-psychotic medications

12. Reported pain score of 2 or more at screening on the 11-point scale numerical pain rating scale-administered after an activity (NPRS-A) following an activity after and walking approximately 10 feet.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Botulinum Neurotoxin Serotype E
Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
Drug:
Placebo
Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.

Locations

Country Name City State
United States Huntington Ambulatory Surgery Center Pasadena California
United States Lotus Clinical Research, LLC Pasadena California

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96) The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule. Every 2 hours from 12 to 96 hours postsurgery
Secondary AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule. Every 2 hours from 0 to 96 hours postsurgery
Secondary AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72) The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule. Every 2 hours from 0 to 72 hours postsurgery
Secondary AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48) The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule. Every 2 hours from 0 to 48 hours postsurgery
Secondary AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24) The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule. Every 2 hours from 0 to 24 hours postsurgery
Secondary AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24) The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule. Every 2 hours from 12 to 24 hours postsurgery
Secondary Participants Overall Assessment of Pain Using the NPRS After Discharge The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. Days 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24 and 26
Secondary Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A) The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately = 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable. 8, 16, 24, 30, 36, 42, 48, 54, 60, 66, 72.78.84, and 96 hours after surgery; Days 8, 15 and 29 after discharge
Secondary Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent. Days 5, 8, 15 and 29
Secondary Number of Doses of Rescue Medications Used Up to 96 hours postsurgery
See also
  Status Clinical Trial Phase
Completed NCT03143959 - Functional Improvement With Abdominoplasty N/A
Active, not recruiting NCT04207047 - Histologic Evaluation of Tissue Following Lutronic System Exposure N/A
Active, not recruiting NCT04712331 - Effect of Abdominal Exercises and Russian Stimulation on The Abdominal Muscles Strength After Abdominoplasty N/A
Completed NCT02949778 - Quadratus Lumborum Block for Abdominoplasty Phase 4
Active, not recruiting NCT01026662 - In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue Phase 2/Phase 3
Withdrawn NCT03770195 - Registry Study for the Use of HEMOBLAST™ Bellows in Abdominoplasty
Terminated NCT02302222 - The Management of Closed Surgical Incisions Resulting From Incisional Hernia Repair and/or Functional Panniculectomy Using the Prevena™ Customizable™ Dressing N/A
Recruiting NCT05939518 - Fluid Therapy and Glycocalyx Shedding During Moderate Surgery N/A
Active, not recruiting NCT05490602 - Comparison Study in Different Sutures Techniques in Reduction of Known Abdominoplasty Complications and Improving Patients' Post-operative Outcomes
Completed NCT01389635 - Abdominoplasty Under Epidural Anesthesia N/A
Recruiting NCT04670224 - Efficiency of the Quadratus Lumborum Block for Post-operative Analgesia in Abdominoplasty Surgery N/A
Recruiting NCT03190876 - Seroma Prevention After Body Contouring Procedures N/A
Recruiting NCT04787874 - Effect of Prehabilitation on Surgical Outcomes of Abdominally-based Plastic Surgery Procedures N/A
Completed NCT01604694 - Ultrasound-guided Transversus Abdominis Plane Block for Analgesia After Abdominoplasty Phase 4
Withdrawn NCT02140385 - Role of Preservation of Scarpa's Fascia in Abdominoplasty N/A
Completed NCT04182880 - Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain Phase 2
Completed NCT03467724 - Treatment of Surgical Scars Following Breast Augmentation, Abdominoplasty or Face Lift N/A
Not yet recruiting NCT02930447 - Evaluation of the Benefit of the Use of Autologous Glue Prepared With RegenKit®-Surgery Device in Abdominoplasty N/A
Enrolling by invitation NCT06043557 - Patient Satisfaction and Reflection on Drain Placement N/A
Completed NCT01331798 - Evaluation of Cohera TissuGlu in the Management of Wound Drainage Following Abdominoplasty Phase 1/Phase 2